Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Mol Life Sci. 2008 Oct;65(20):3231-40. doi: 10.1007/s00018-008-8228-6.

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Author information

1
Institute for Cellular Therapeutics, University of Louisville School of Medicine, Louisville, KY, 40202, USA.

Abstract

The development of non-infectious subunit vaccines greatly increases the safety of prophylactic immunization, but also reinforces the need for a new generation of immunostimulatory adjuvants. Because adverse effects are a paramount concern in prophylactic immunization, few new adjuvants have received approval for use anywhere in the developed world. The vaccine adjuvant monophosphoryl lipid A is a detoxified form of the endotoxin lipopolysaccharide, and is among the first of a new generation of Toll-like receptor agonists likely to be used as vaccine adjuvants on a mass scale in human populations. Much remains to be learned about this compound's mechanism of action, but recent developments have made clear that it is unlikely to be simply a weak version of lipopolysaccharide. Instead, monophosphoryl lipid A's structure seems to have fortuitously retained several functions needed for stimulation of adaptive immune responses, while shedding those associated with pro-inflammatory side effects.

PMID:
18668203
PMCID:
PMC2647720
DOI:
10.1007/s00018-008-8228-6
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center